Drug intelligence / Profile preview

Fecal microbiota transplant (UTHealth Houston)

Development stage: Unknown
Lead developer: University of Texas Health Science Center at Houston
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral, Rectal

Overview

Fecal microbiota transplant (UTHealth Houston) is an investigational live biotherapeutic product developed by The University of Texas Health Science Center at Houston (UTHealth) for the treatment of recurrent Clostridioides difficile-associated diarrhea (CDAD). The active ingredient is processed fecal microbiota from healthy, screened donors. [2, 14] Its mechanism of action is the restoration of healthy gut microbiome diversity, which has been disrupted by the infection and antibiotic treatments, thereby outcompeting the pathogenic bacteria. [2, 10] This biologic therapy is being investigated in multiple formulations, including fresh, frozen, and lyophilized (freeze-dried) preparations, which are administered via colonoscopy, retention enema, or as oral capsules. [2, 3, 6] The product is being developed under FDA IND #17059 and has been studied in Phase 1/2 clinical trials. [3]

Other names: fecal microbiota-The University of Texas Health Science Center, Houston-Clostridium difficile-associated diarrhea

Beyond the preview

Go deeper on Fecal microbiota transplant (UTHealth Houston).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fecal microbiota transplant (UTHealth Houston).

Explore the full profile